Fig. 5: Expression of TLR9 in LM biospecimens and MDSCs. | Cancer Gene Therapy

Fig. 5: Expression of TLR9 in LM biospecimens and MDSCs.

From: Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition

Fig. 5

A Protein lysates obtained from LM patient biospecimens were evaluated for TLR7 and TLR9 by western blotting. GAPDH was used as housekeeping protein control. WB was performed on two different runs (#1 to #5 on one run and #6 and #7 were performed in a different run) B Total RNA was isolated from the same biospecimen and expression of TLR9 was quantified by qRT-PCR. RPL-27 gene was used as housekeeping control. Representative data of 4 of 7 biospecimens is shown here due to sample unavailability). C IL6 (20 ng/ml) + GMCSF (20 ng/ml) stimulated PBMCs grown in chamber slides were fixed and stained with TLR9 (green), CD11b (red) and HLA-DR (yellow) antibodies and DAPI (blue) used for nuclear staining. IF images demonstrate surface expression of TLR9 in CD11b+HLA-DR− cells. Representative of three different experiment using PBMCs from three different donors. D WB of IL6 (20 ng/ml) + GMCSF (20 ng/ml) treated PBMCs showing expression of TLR9. GAPDH was used as control. (Representative of two out of four donors).

Back to article page